Diversity & Inclusion. Women in EP. Leadership across bias. #EHRASummit2026 — Tallinn 🇪🇪 Uncomfortable questions. No easy answers. What does it mean to build a career in EP without a template? How do we make modern electrophysiology accessible — regardless of gender, geography, or socioeconomic status? Country perspectives from 🇳🇱 🇹🇳 🇪🇸 reminded us: barriers differ, urgency doesn't. Electrophysiology should reflect the patients it serves — in its workforce, leadership, and science. That work continues. 💙 @escardio

⏳ONLY 12 days left ‼️ Applications for the EHRA Level 3 | DAS-CAM programme close on 2️⃣2️⃣ June 2026. 👉Join a unique leadership and innovation programme. Deadline extended - don’t miss your chance to apply. 🚀 🔗dascam.org @kvernooy

Most EP specialists master the craft. Few learn to lead the field. #EHRA_ESC @DASCAMaastricht exists for that second group — and the application deadline has just been extended to 22 June 2026! This isn't another CME box to tick. It's the highest level of #EHRA_ESC's flagship educational programme, co-designed with Maastricht University, built specifically for arrhythmia specialists who want to move from clinical excellence into real leadership — in research, in institutions, in the future of EP. You leave with: 🎓 A Certificate of Advanced Studies from Maastricht University 🔬 An optional PhD pathway 🤝 Direct mentorship from European leaders in the field 📚 4 intensive in-person modules online introductory session ⚡ ~55 hours of structured learning per module — small groups, hands-on, no fluff This is where the next generation of EP leaders is shaped. The window is still open — but not for long. Apply by 22 June 2026 👉 🔗 bit.ly/4fyZKWf @kvernooy @JordiHeijman @EmmaSvennberg @Dominik_Linz @mspartalis5 @KurathKoller @DS_DoreenSch @Phiso_de @SergeBoveda @joselmerino @DavidDuncker @simovicst

In the OPTION trial, 1,600 patients with #AFib undergoing catheter ablation were randomized to #LAAO or OAC. At 36 months, LAAO reduced non–procedure-related major or clinically relevant nonmajor bleeding (8.5% vs 18.1%) and was noninferior for the composite of death, stroke, or systemic embolism (5.3% vs 5.8%). 🖇️ tinyurl.com/5fp8nk5z #EHRAtopicweek #Epeeps @NEJM

📢 In the CHAMPION-AF trial, 3,000 patients with #AFib suitable for #DOAC therapy were randomized to #LAAO or DOACs. At 3 years, LAAO was noninferior for the composite of CV death, stroke, or systemic embolism (5.7% vs 4.8%), while reducing non–procedure-related bleeding (10.9% vs 19.0%; HR 0.55) 🖇️ tinyurl.com/4wua36vy #EHRAtopicweek #Epeeps @NEJM

👀Take a look at this #EHRA survey about #Afib ablation in elderly patients. Very important topic and <5 minutes to complete! @ManningerMartin @Dominik_Linz @simovicst @jongichun @kvernooy research.net/r/AFtreatmentin…

Long awaited #LAAO #EHRA_ESC Cardio Talk podcast

🌟Unlock your leadership potential in cardiac arrhythmia management 🩺 Join our #DASCAM 2026 programme (#EHRA level 3). 🔗 dascam.org 👉 EXTENDED DEADLINE until 22 June 2026, DO NOT MISS it !

🫀 #EHRATopicWeek Focal or reentrant? Modern insights into atrial tachycardia What we once called “focal” AT is often far more complex. Traditionally, focal AT (FAT) was defined as activation spreading centrifugally from a discrete site. Today, high-resolution mapping has revealed that many apparently focal tachycardias are actually tiny localized reentrant circuits — micro-reentrant ATs (MiRATs). 📌 True focal AT is mainly driven by: • enhanced automaticity • triggered activity Meanwhile, localized reentrant ATs (LRATs) commonly occur in scarred atria or after previous ablation procedures and are characterized by slow conduction and long fractionated electrograms. ⚡ Modern EP increasingly relies on: • high-density mapping • entrainment mapping • electrogram interpretation • detailed anatomical understanding Common AT locations include the crista terminalis, pulmonary veins, left atrial ridge, septal regions, and prior ablation scars. 💡 The more we map atrial tachycardias, the more we understand that “focal” does not always mean focal. 📖 Read more in the #EHRA_ESC Consensus document on Atrial Tachycardias 👉bit.ly/4wk5sBn @escardio @EuropaceEiC

⚡ #EHRATopicWeek on Atrial Tachycardias Catheter ablation has become the preferred treatment strategy for most symptomatic or recurrent ATs, while antiarrhythmic drug therapy often shows limited long-term efficacy. 📌 Key concepts from the latest evidence: • Beta-blockers and calcium channel blockers remain important for rate control • Catheter ablation is now first-line in many patients • High-resolution electroanatomical mapping has transformed our understanding of AT circuits • Entrainment and activation mapping remain essential tools for distinguishing focal vs reentrant mechanisms • Pulsed-field ablation and ultra-high-resolution mapping are opening a new era in AT treatment 💡 Success in AT ablation depends on identifying the “critical isthmus” — the key region maintaining the arrhythmia — while durable bidirectional block is increasingly recognized as a crucial procedural endpoint. Importantly, recurrence remains a major challenge, especially in patients with structural heart disease, prior AF ablation, or extensive atrial scarring Find out more in the #EHRA_ESC Consensus document on Atrial Tachycardias 👉bit.ly/4wk5sBn @escardio @EuropaceEiC

🔍 #EHRATopicWeek on Atrial Tachycardias Atrial Tachycardia is more complex than we once thought Traditionally, rapid regular atrial arrhythmias were divided into “atrial tachycardia” and “atrial flutter” based mainly on ECG appearance. Today, high-resolution mapping shows these distinctions are often oversimplified. 📌 Current concepts classify all regular atrial rhythms >100 bpm as AT: • Non-reentrant AT • Reentrant AT (localized or macro-reentrant) Importantly, many arrhythmias previously labeled as “flutter” may actually represent different AT mechanisms. ⚡ Differentiating AT from organized AF can be challenging, especially in scarred atria or after ablation. ECGs, EP studies, intracardiac mapping, and even wearable devices all play an important role in diagnosis. 💡 Precise classification matters — for diagnosis, treatment strategy, and improving ablation outcomes. Find out more in the #EHRA_ESC Consensus document on Management of patients with atrial tachycardia 🔗bit.ly/4wk5sBn @escardio @EuropaceEiC

🎙️ New EHRA CardioTalk podcast episode is out! This month we are tackling one of the most clinically demanding scenarios in electrophysiology — Re-Do atrial fibrillation procedures. When does a patient need a second (or third) ablation? What are the key considerations, pitfalls, and strategies? 🤔 Join @sozi81 @simovicst @JacopoImberti sharing their expertise 👉 Listen here: esc365.escardio.org/event/25… #EHRAtopicweek @escardio

⚠️ Arrhythmic mitral valve prolapse. One of the most complex challenges in modern EP Risk stratification. Sudden cardiac death prevention. High stakes — and not always clear-cut answers. #EHRA_ESC has provided a consensus framework. But how is it actually being applied in real-world clinical practice? We want to hear from you 🫵 If you manage patients with AMVP, your insights matter. This short survey is gathering frontline perspectives on how these recommendations translate from guidelines to the bedside. 📋 Take the survey 👇 🔗 research.net/r/riskstratific…

🌟 The future of electrophysiology is bright — and it has names. Meet Corentin Chaumont, Tine Prolič Kalinšek, and @ManningerMartin — three Young Ambassadors shaping the next chapter of the EP community through EHRA. In "Rising Stars of EHRA: Young EP Trailblazers", they open up about what it means to be an early-career electrophysiologist today — the challenges, the opportunities, and the power of being part of a global network that has your back. Whether you're just starting your EP journey or looking to get more involved in the #EHRA_ESC community, this one's for you. 🎥 Watch now 👇 🔗 esc365.escardio.org/session/…

What a great success of the 1st #EHRA_ESC Journal club discussing the LEFT-BUNDLE CRT trial with @micaela_ebert @HaranBurri @OCanoPerez @ZacharyWhinnett More episodes to come soon! @escardio

The 1st #EHRA_ESC Journal Club is scheduled for the 6th of May! Register 👇🏻and discuss the LEFT-BUNDLE CRT trial

Immediately following the #LBCT presentation at #HRS2026, Heart Rhythm TV host @MehakDhande, sat down with @sean_pokorney, and Roopinder K. Sandhu, MD, MPH, FHRS, to discuss Centers of Excellence Optimal Management Pathways for Atrial Fibrillation Specialty Services Early Rhythm Control Treatment Care Pathway: Primary Results of the COMPASS Heart Rhythm Society Quality Improvement Initiative. See the full discussion here #EPeeps ➡️ bit.ly/4cwtdyc

#EHRAroundTheGlobe from #HRS2026

👩🏻‍⚖️Passing the gavel from one woman in EP to another!! Congrats Dr Mina Chung (@EP_mom1) on a great year as @HRSonline President! Welcome to Dr @SanaAlkhatib9, our new #HRS2026 - #HRS2027 #MadamePresident!! #WomeninEP #EPeeps

Case-based Innovations & Procedural Strategy in #AF, #VT, & Conduction system #pacing! Led by @Drdevignair @Mel_Gunawardene @EP_mom1 Come to the grand Ballroom now s100! #HRS2026